PTEN deletion enhances survival, neurite outgrowth and function of dopamine neuron grafts to mitopark mice

Brain

Volumn 135, Issue 9, 2012, Pages 2736-2749

  Zhang, Yajun ^a   Granholm, Ann Charlotte ^b   Huh, Kyounghee ^a   Shan, Lufei ^a   Diaz Ruiz, Oscar ^a   Malik, Nasir ^a   Olson, Lars ^c   Hoffer, Barry J ^d   Lupica, Carl R ^a   Hoffman, Alexander F ^a   Bäckman, Cristina M ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; mTOR; striatal innervation; substantia nigra; transplantation

Indexed keywords

DOPAMINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; GENE DELETION; GENE INACTIVATION; GRAFT SURVIVAL; LOCOMOTION; MESENCEPHALON; MOUSE; NERVE FIBER GROWTH; NERVE GRAFT; NEURITE; NONHUMAN; PARKINSON DISEASE; POTENTIOMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY CHAIN; SIGNAL TRANSDUCTION;

EID: 84866393562     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws196     Document Type: Article

References (56)

1. Abe N, Cavalli V. Nerve injury signaling. Curr Opin Neurobiol 2008; 18: 276-83.
2. Ahn YH, Bensadoun JC, Aebischer P, Zurn AD, Seiger A, Bjorklund A, et al. Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with co-implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor. Brain Res Bull 2005; 66: 135-42.
3. Andereggen L, Meyer M, Guzman R, Ducray AD, Widmer HR. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease. Brain Res 2009; 1276: 39-49.
4. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 1997; 12: 33-8.
5. Backman CM, Malik N, Zhang Y, Shan L, Grinberg A, Hoffer BJ, et al. Characterization of a mouse strain expressing Cre recombinase from the 3' untranslated region of the dopamine transporter locus. Genesis 2006; 44: 383-90.
6. Beal MF. Parkinson's disease: a model dilemma. Nature 2010; 466: S8-10.
7. Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR. A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 1998; 18: 5301-10.
8. Bjorklund L, Vidal N, Stromberg I. Lazaroid-enhanced survival of grafted dopamine neurons does not increase target innervation. Neuroreport 1998; 9: 2815-9.
9. Bove J, Martinez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 2011; 12: 437-52.
10. Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res 2010; 184: 265-94.
11. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-68.
12. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and-independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001; 11: 297-305.
13. Burke RE. Intracellular signalling pathways in dopamine cell death and axonal degeneration. Prog Brain Res 2010; 183: 79-97.
14. Burke RE, Cadet JL, Kent JD, Karanas AL, Jackson-Lewis V. An assessment of the validity of densitometric measures of striatal tyrosine hydroxylase-positive fibers: relationship to apomorphine-induced rotations in 6-hydroxydopamine lesioned rats. J Neurosci Methods 1990; 35: 63-73.
15. Chang N, El-Hayek YH, Gomez E, Wan Q. Phosphatase PTEN in neuronal injury and brain disorders. Trends Neurosci 2007; 30: 581-6.
16. Cheng HC, Kim SR, Oo TF, Kareva T, Yarygina O, Rzhetskaya M, et al. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J Neurosci 2011; 31: 2125-35.
17. Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev 2010; 3: 374-91.
18. Chou J, Greig NH, Reiner D, Hoffer BJ, Wang Y. Enhanced survival of dopaminergic neuronal transplants in hemiparkinsonian rats by the p53 inactivator PFT-alpha. Cell Transplant 2011; 20: 1351-9.
19. Christie KJ, Webber CA, Martinez JA, Singh B, Zochodne DW. PTEN inhibition to facilitate intrinsic regenerative outgrowth of adult peripheral axons. J Neurosci 2010; 30: 9306-15.
20. Cragg SJ, Clarke DJ, Greenfield SA. Real-time dynamics of dopamine released from neuronal transplants in experimental Parkinson's disease. Exp Neurol 2000; 164: 145-53.
21. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-27.
22. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron 2010; 66: 646-61.
23. Diaz-Ruiz O, Zapata A, Shan L, Zhang Y, Tomac AC, Malik N, et al. Selective deletion of PTEN in dopamine neurons leads to trophic effects and adaptation of striatal medium spiny projecting neurons. PLoS One 2009; 4: e7027.
24. Domanskyi A, Geissler C, Vinnikov IA, Alter H, Schober A, Vogt MA, et al. Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models. FASEB J 2011; 25: 2898-910.
25. Ekstrand MI, Galter D. The MitoPark Mouse-an animal model of Parkinson's disease with impaired respiratory chain function in dopa-mine neurons. Parkinsonism Relat Disord 2009; 15 (Suppl 3): S185-8.
26. Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 2007; 104: 1325-30.
27. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. San Diego: Academic Press; 1997.
28. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi JX, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992; 327: 1549-55.
29. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-9.
30. Freed CR, Zhou W, Breeze RE. Dopamine cell transplantation for Parkinson's disease: the importance of controlled clinical trials. Neurotherapeutics 2011; 8: 549-61.
31. Galter D, Pernold K, Yoshitake T, Lindqvist E, Hoffer B, Kehr J, et al. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease. Genes Brain Behav 2010; 9: 173-81.
32. Gerfen CR, Miyachi S, Paletzki R, Brown P. D1 dopamine receptor super-sensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 2002; 22: 5042-54.
33. Good CH, Hoffman AF, Hoffer BJ, Chefer VI, Shippenberg TS, Backman CM, et al. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB J 2011; 25: 1333-44.
34. Harvey BK, Wang Y, Hoffer BJ. Transgenic rodent models of Parkinson's disease. Acta Neurochir 2008; 101 (Suppl): 89-92.
35. Kim SR, Chen X, Oo TF, Kareva T, Yarygina O, Wang C, et al. Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol 2011; 70: 110-20.
36. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990a; 247: 574-7.
37. Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, et al. Neural transplantation in Parkinson's disease: the Swedish experience. Prog Brain Res 1990b; 82: 729-34.
38. Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 1989; 46: 615-31.
39. Lindvall O, Rehncrona S, Gustavii B, Brundin P, Astedt B, Widner H, et al. Fetal dopamine-rich mesencephalic grafts in Parkinso's disease. Lancet 1988; 2: 1483-4.
40. Lindvall O, Sawle G, Widner H, Rothwell JC, Bjorklund A, Brooks D, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172-80.
41. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994; 17 (Suppl 2): S32-44.
42. Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A, et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg 2000; 92: 863-9.
43. Namikawa K, Honma M, Abe K, Takeda M, Mansur K, Obata T, et al. Akt/protein kinase B prevents injury-induced motoneuron death and accelerates axonal regeneration. J Neurosci 2000; 20: 2875-86.
44. Olanow CW, Kordower JH, Lang AE, Obeso JA. Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol 2009; 66: 591-6.
45. Park KK, Liu K, Hu Y, Kanter JL, He Z. PTEN/mTOR and axon regeneration. Exp Neurol 2010; 223: 45-50.
46. Park KK, Liu K, Hu Y, Smith PD, Wang C, Cai B, et al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 2008; 322: 963-6.
47. Perier C, Bove J, Vila M. Mitochondria and programmed cell death in Parkinson's disease: apoptosis and beyond. Antioxid Redox Signal 2011; 16: 883-95.
48. Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R, et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 2000; 48: 689-95.
49. Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, et al. Clinical-pathological study of levodopa complications. Mov Disord 2002; 17: 289-96.
50. Read DE, Gorman AM. Involvement of Akt in neurite outgrowth. Cell Mol Life Sci 2009; 66: 2975-84.
51. Rinne UK, Laihinen A, Rinne JO, Nagren K, Bergman J, Ruotsalainen U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990; 5: 55-9.
52. Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTENless means more. Dev Biol 2004; 273: 175-84.
53. Tornqvist N, Bjorklund L, Almqvist P, Wahlberg L, Stromberg I. Implantation of bioactive growth factor-secreting rods enhances fetal dopaminergic graft survival, outgrowth density, and functional recovery in a rat model of Parkinson's disease. Exp Neurol 2000; 164: 130-8.
54. Torres EM, Dowd E, Dunnett SB. Recovery of functional deficits following early donor age ventral mesencephalic grafts in a rat model of Parkinson's disease. Neuroscience 2008; 154: 631-40.
55. Torres EM, Monville C, Gates MA, Bagga V, Dunnett SB. Improved survival of young donor age dopamine grafts in a rat model of Parkinson's disease. Neuroscience 2007; 146: 1606-17.
56. Tsui A, Isacson O. Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease. J Neurol 2011; 258: 1393-405.